Table 4 Outcomes of the COVID-19 patients with HCV
Treatment | Outcome | p value | OR (95%CI) | |
|---|---|---|---|---|
Survived (n = 37) | Died (n = 32) | |||
No treatment, n (%) | 6 (16.2%) | 14 (43.8%) | 0.01* | 0.25 (0.08–0.76) |
Triple therapy, n (%) | 15 (40.5%) | 4 (12.5%) | 0.009* | 4.77 (1.39–16.43) |
Ribavirin and interferon, n (%) | 8 (21.6 %) | 12 (37.5%) | 0.15 NS | 0.26 (0.16–1.33) |
Double therapy, n (%) | 6 (16.2%) | 2 (6.3%) | 0.20 NS | 2.90 (0.54–15.53) |
Triple+ribavirin and interferon, n (%) | 2 (5.4%) | 0 (0%) | 0.57 NS | – |